000			01973cam a2200265 4500500
005			20251214025751.0
041			_afre
042			_adc
100	1	0	_aAndrès, Emmanuel _eauthor
700	1	0	_aTerrade, Jean Edouard _eauthor
700	1	0	_aJannot, Xavier _eauthor
700	1	0	_aHabib, Charlène _eauthor
700	1	0	_aGhiura, Cosmina _eauthor
700	1	0	_aTaquet, Marie-Caroline _eauthor
700	1	0	_aDiallo, Alpha _eauthor
700	1	0	_aNasco, Edward _eauthor
700	1	0	_aDalmas, Marie-Caroline _eauthor
700	1	0	_aLorenzo-Villalba, Noël _eauthor
245	0	0	_aThe role of thrombophilia testing in 2025: An update for medical practice and points for consideration
260			_c2025.
500			_a17
520			_aThrombophilia testing aims to identify abnormalities that promote venous thrombosis, but its use is now limited. It is only recommended in specific cases: recurrent thrombosis, thrombosis at unusual sites, a family history of early-onset events, or suspected antiphospholipid syndrome. Testing includes the detection of genetic mutations (factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] mutations) and deficiencies in antithrombin, protein C, and protein S, as well as elevated homocysteine levels and acquired abnormalities such as antiphospholipid syndrome (APS). It may also include testing for myeloproliferative syndromes and paroxysmal nocturnal hemoglobinuria. However, its impact on patient management remains limited, as the presence of hereditary thrombophilia does not always alter the duration of anticoagulant treatment. Furthermore, the excessive use of these tests can lead to over-medicalization and significant costs without clear clinical benefit.
786	0		_nCahiers Santé Médecine Thérapeutique | 34 | 4 | 2025-10-01 | p. 273-278 | 2780-8858
856	4	1	_uhttps://stm.cairn.info/journal-cahiers-sante-medecine-therapeutique-2025-4-page-273?lang=en&redirect-ssocas=7080
999			_c1572957 _d1572957